U.S. President Donald Trump has mandated 100% tariffs on imported branded pharmaceuticals. Drugmakers can avoid these tariffs by agreeing to local pricing arrangements or committing to domestic production. This move, aimed at lowering drug costs, substantially impacts small and mid-sized pharmaceutical companies.
Meanwhile, a significant trade deal between the U.S. and the UK grants British-made medicines tariff-free access to the U.S. market. In return, the UK will pay higher prices for new medicines. The agreement is part of a broader trade accord finalized last year.
Additionally, changes in the U.S. Global Health Supply Chain Program are raising concerns about potential service disruptions in delivering critical healthcare supplies for HIV and malaria. This occurs alongside advancements in treatment options, such as surgery for early-stage lung cancer, even for patients over 80.